Interpace Biosciences, Inc. (IDXG) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate Interpace Biosciences, Inc.'s investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
0.22
Strong
WeakModerateStrong
P/B Ratio
0.24
Strong
WeakModerateStrong
Earnings Yield
4.52%
Strong
WeakModerateStrong
Profitability Health
2025Return on Equity
109.89%
Strong
WeakModerateStrong
Operating Margin
10.55%
Moderate
WeakModerateStrong
Net Profit Margin
63.46%
Strong
WeakModerateStrong
Growth Indicators
2025Revenue Growth
-17.47%
Weak
WeakModerateStrong
Net Income Growth
266.68%
Strong
WeakModerateStrong
EPS Growth
290.85%
Strong
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
1.94
Moderate
WeakModerateStrong
Quick Ratio
1.72
Strong
WeakModerateStrong
Asset Turnover
1.14x
Strong
WeakModerateStrong
Inventory Turnover
13.10x
Strong
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
100.62%
Strong
WeakModerateStrong
EV / Free Cash Flow
0.75x
Strong
WeakModerateStrong
Net Debt / EBITDA
-0.28x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
0.924
Moderate
WeakModerateStrong
Return on Invested Capital
14.00%
Weak
WeakModerateStrong
Cash Conversion Cycle
56.52 days
Weak
WeakModerateStrong
Fortress screener guardrails
2/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for IDXG.
View Financial Statements